http://thomas.loc.gov/cgi-bin/query/F?c109:1:./temp/~c109yEL4S2:e956:
S.1873
Biodefense and Pandemic Vaccine and Drug Development Act of 2005 (Introduced in
Senate)
--------------------------------------------------------------------------------
SECTION 1. SHORT TITLE.
This Act may be cited as the `Biodefense and Pandemic Vaccine and Drug
Development Act of 2005'.
SEC. 2. TABLE OF CONTENTS.
The table of contents of this Act is as follows:
Sec. 1. Short title.
Sec. 2. Table of contents.
Sec. 3. Biomedical Advanced Research and Development Agency.
Sec. 4. Clarification of countermeasures covered by Project BioShield.
Sec. 5. Orphan drug market exclusivity for countermeasure products.
Sec. 6. Liability protections for pandemics, epidemics, and countermeasures.
Sec. 7. Compensation.
Sec. 8. Rebates and grants for research development, and manufacturing of
vaccines, qualified countermeasures and pandemic or epidemic products.
Sec. 9. Technical assistance.
Sec. 10. Animal models for certain diseases.
Sec. 11. Animal Model/Research Tool Scientific Advisory Committee.
Sec. 12. Collaboration and coordination.
Sec. 13. Procurement.
Sec. 14. National Pathology Center.
SEC. 3. BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AGENCY.
Title III of the Public Health Service Act (42 U.S.C. 241 et seq.) is amended by
inserting after section 319K the following:
`SEC. 319L. BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AGENCY.
`(a) Definitions- In this section:
`(1) BARDA- The term `BARDA' means the Biomedical Advanced Research and
Development Agency.
`(2) FUND- The term `Fund' means the Biodefense Medical Countermeasure
Development Fund established under subsection (d).
`(3) OTHER TRANSACTIONS- The term `other transactions' means transactions, other
than procurement contracts, grants, and cooperative agreements, including
transactions for prototypes, as provided to the Secretary of Defense under
section 2371 of title 10, United States Code.
`(4) QUALIFIED COUNTERMEASURE- The term `qualified countermeasure' has the
meaning given such term in section 319F-1.
`(5) QUALIFIED COUNTERMEASURE AND QUALIFIED PANDEMIC OR EPIDEMIC PRODUCT
ADVANCED RESEARCH AND DEVELOPMENT-
`(A) IN GENERAL- The term `qualified countermeasure and qualified pandemic or
epidemic product advanced research and development' means any applied research,
testing, or evaluation (including those conducted on humans or animals), related
to the safety or effectiveness, that is required for approval, clearance, or
licensing by the Secretary under this Act or the Federal Food, Drug, and
Cosmetic Act, of such countermeasure or pandemic or epidemic product to
diagnose, mitigate, prevent, or treat harm from a deliberate, accidental, or
natural exposure to a chemical, biological, radiological, or nuclear agent,
particularly such exposure resulting from an act of terrorism or potential
pandemic infectious disease.
`(B) INCLUSION- The term under subparagraph (A) includes any investigation to
improve the manufacturing, formulation, finish, fill, delivery, or shelf-life of
such qualified countermeasures or qualified pandemic or epidemic products.
`(6) QUALIFIED PANDEMIC OR EPIDEMIC PRODUCT- The term `qualified pandemic or
epidemic product' has the meaning given the term in section 319F-3(c)(5).
`(7) SECURITY COUNTERMEASURE- The term `security countermeasure' has the meaning
given such term in section 319F-2.
`(8) PERSON- The term `person' includes an individual, partnership, corporation,
association, entity, or public or private corporation, including a Federal,
State, or local agency or department.
`(b) BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AGENCY-
`(1) ESTABLISHMENT- There is established within the Department of Health and
Human Services, the Biomedical Advanced Research and Development Agency.
`(2) PURPOSE- It shall be the purpose of the BARDA to coordinate and oversee
activities that support and accelerate qualified countermeasure or qualified
pandemic or epidemic product (referred to in this section as `countermeasure or
product') advanced research and development by--
`(A) directing and coordinating collaboration among the Department of Health and
Human Services, other Federal agencies, relevant industries, academia, and other
persons, with respect to such advanced research and development;
`(B) supporting countermeasure and product advanced research and development;
`(C) recommending approaches to modernize and streamline the countermeasure or
product development process and reduce regulatory burdens with respect to
procurement of security countermeasures and qualified pandemic or epidemic
products; and
`(D) supporting innovation to reduce the time and cost of countermeasure and
product advanced research and development.
`(3) DIRECTOR- The BARDA shall be headed by a Director (referred to in this
section as the `Director') who shall--
`(A) be appointed by the President, with the advice and consent of the Senate;
`(B) report to the Secretary; and
`(C) serve as the principal advisor to the Secretary on countermeasure and
product advanced research and development.
`(4) DUTIES OF DIRECTOR-
`(A) COLLABORATION- To carry out the purpose described in paragraph (2)(A), the
Secretary, acting through the Director, shall--
`(i) increase appropriate communication between the Federal Government and
relevant industries, academia, and other interested persons with respect to
countermeasure and product advanced research and development by establishing
transparent, expeditious, and direct processes to--
`(I) facilitate regular, ongoing communication regarding the processes
established under subparagraph (C)(ii) and new countermeasures or products of
interest;
`(II) solicit research and associated data on potential countermeasures and
products and related technologies; and
`(III) provide technical assistance with respect to such processes and the Food
and Drug Administration approval process;
`(ii) at least annually--
`(I) convene meetings with representatives from relevant industries, academia,
other Federal agencies, international agencies, and other interested persons;
and
`(II) sponsor relevant biodefense countermeasure technology demonstrations;
`(iii) carry out the activities described in subsection (g) of section 2 of the
Clayton Act; and
`(iv) encourage and coordinate countermeasure or product advanced research and
development, including by convening working groups as identified in paragraph
(5).
`(B) SUPPORT ADVANCED RESEARCH AND DEVELOPMENT- To carry out the purpose
described in paragraph (2)(B), the Secretary, acting through the Director,
shall--
`(i) conduct continuous searches and support calls for potential countermeasures
or products for drugs, biological products, devices, or research tools to
diagnose, mitigate, prevent, or treat harm from existing, emerging, or possible
chemical, biological, radiological, and nuclear agents or potential pandemic
infectious diseases that threaten public health and national security, as
identified by the Assistant Secretary for Public Health Emergency Preparedness;
`(ii) direct the countermeasure and product advanced research and development
activities of the Department of Health and Human Services, in consultation with
the Assistant Secretary for Public Health Emergency Preparedness, the Director
of the National Institutes of Health, the Director of the Centers for the
Disease Control and Prevention, and the Commissioner of Food and Drugs; and
`(iii) award contracts, grants, cooperative agreements, and enter into other
transactions, to include use of simplified acquisition authorities provided
under sections 319F-1 and 319F-2(c)(7)(C)(iii), to public and private persons,
including for-profit and nonprofit persons, federally funded research and
development centers, and universities, to--
`(I) support the cost of countermeasure and product advanced research and
development; and
`(II) ensure accelerated development of countermeasures and products.
`(C) STREAMLINE PROCESSES- To carry out the purpose described in paragraph
(2)(C), the Secretary, acting through the Director, shall--
`(i) receive from the Assistant Secretary for Public Health Emergency
Preparedness, requirements for national civilian biodefense needs, particularly
countermeasures or products and other technologies, to diagnose, mitigate,
prevent, or treat harm from existing, emerging, or potential chemical,
biological, radiological, or nuclear agents or potential pandemic infectious
diseases;
`(ii) establish transparent, expeditious, and direct processes for selecting
promising countermeasures and products, supporting them through advanced
research and development and recommending them for procurement;
`(iii) establish an office within the BARDA, in consultation with the
Commissioner of Food and Drugs, to--
`(I) facilitate regular and ongoing communication between the BARDA and the Food
and Drug Administration regarding the status of BARDA advanced research and
development activities;
`(II) ensure that such activities are coordinated with the approval requirements
of the Food and Drug Administration, with the goal of expediting the development
and approval of countermeasures and products; and
`(III) connect interested persons with additional technical assistance made
available under section 565 of the Federal Food, Drug, and Cosmetic Act;
`(iv) coordinate with the Food and Drug Administration to facilitate regulatory
review and approval of promising classes of countermeasures or products through
the development of research tools; and
`(v) recommend to the Secretary, through the Assistant Secretary for Public
Health Emergency Preparedness, procurement of the most promising eligible
security countermeasures or qualified pandemic or epidemic products identified
in clause (i).
`(D) SUPPORTING INNOVATION- To carry out the purpose described in paragraph
(2)(D), the Secretary, acting through the Director, shall award contracts,
grants, cooperative agreements, or enter into other transactions, to include use
of simplified acquisition authorities provided under sections 319F-1 and
319F-2(c)(7)(C)(iii), to the entities described in subparagraph (B)(iii), to
promote innovation in technologies supporting the advanced research and
development and production of qualified or security countermeasures or qualified
pandemic or epidemic products, such as research tools, manufacturing,
countermeasure administration, storage, and bioinformatics and other devices.
`(E) OTHER DUTIES-
`(i) IN GENERAL- The Director may--
`(I) prepare and submit to the President and Congress, an annual budget estimate
for qualified countermeasure and pandemic or epidemic product advanced research
and development and other BARDA activities, after opportunity for comment by the
Secretary; and
`(II) receive from the President and the Office of Management and Budget
directly all funds appropriated by Congress for obligation and expenditure by
the BARDA.
`(ii) SECRETARY DUTIES- The Secretary, acting through the Director, may--
`(I) enter into such contracts, leases, cooperative agreements, or other
transactions, as may be necessary to carry out the functions of BARDA, without
regard to section 3648 and 3709 of the Revised Statutes of the United States (31
U.S.C. 3324(a) and (b)), (41 U.S.C. 5), with any public agency, any firm,
association, corporation, or educational institution, or any other person;
`(II) support advanced research and development and innovation of potential
countermeasures or products by highly qualified foreign nationals outside the
United States that may inure to the benefit of the American people and
collaborative research involving American and foreign participants;
`(III) administer grants using milestone-based awards and payments; and
`(IV) establish 1 or more federally funded research and development centers or
university affiliated research centers in accordance with section 253(c)(3) of
title 41, United States Code.
`(5) VULNERABLE POPULATIONS- In carrying out the activities under this section,
the Director, in consultation with the Vulnerable Populations Working Group, may
give priority to supporting and facilitating advanced research and development
of countermeasures or products, and formulations of countermeasures or products,
that are likely to be safe and effective for pediatric populations, pregnant
women, and other vulnerable populations.
`(6) WORKING GROUPS-
`(A) IDENTIFICATION OF TECHNOLOGIES-
`(i) IN GENERAL- The Director may establish and convene, or enter into a
contract with a public or private research institution to convene, one or more
working groups that consists of experts on countermeasure technology to identify
innovative technologies that have the potential to be developed as
countermeasures or products.
`(ii) MEETINGS- A working group established under clause (i) shall participate
in regular meetings with sponsors of countermeasures, products, or related
technologies to--
`(I) review the scientific evidence or concept of such countermeasures,
products, or related technologies;
`(II) provide guidance on research protocols or studies; and
`(III) provide guidance on the regulatory approval process for countermeasures,
products, and related technologies.
`(iii) RECOMMENDATIONS- Not later than 30 days after each meeting with a sponsor
of a countermeasure, product, or related technology, the working group shall
make recommendations to the Director concerning such countermeasure, product, or
related technology.
`(iv) CONFIDENTIALITY- Any commercial confidential or proprietary information
that is disclosed to the working group in a meeting under this section shall
remain confidential and shall not be disclosed other than to the Secretary or
the Director, or their designees.
`(v) CONSTRUCTION- Nothing in this subparagraph shall be construed to prohibit a
sponsor from meeting with the Director to discuss potential countermeasures,
products, or related technologies.
`(B) PUBLIC WORKING GROUP- The Director may establish and convene one or more
working groups composed of private citizens and officials of Federal, State, and
local governments to advise such Director with respect to the functions of the
BARDA and the Director.
`(C) VULNERABLE POPULATIONS WORKING GROUP- The Director shall establish and
convene a Vulnerable Populations Working Group composed of experts on pediatric
populations, pregnant women, and other vulnerable populations to advise such
Director with respect to--
`(i) supporting and facilitating advanced research and development of
countermeasures, and formulations of countermeasures, that are safe and
effective for such populations; and
`(ii) other activities of the BARDA that effect such populations.
`(7) PERSONNEL AUTHORITIES-
`(A) SPECIALLY QUALIFIED SCIENTIFIC AND PROFESSIONAL PERSONNEL- In hiring
personnel for the BARDA, the Director shall have the hiring and management
authorities described in section 1101 of the Strom Thurmond National Defense
Authorization Act for Fiscal Year 1999 (5 U.S.C. 3104 note; Public Law 105-261).
With respect to the personnel of the BARDA, the term of appointments for
employees referred to under subsection (c)(1) of that section may not exceed 5
years before the granting of any extension under subsection (c)(2) of that
section.
`(B) SPECIAL CONSULTANTS- The Director may accept special consultants as
personnel for the BARDA under section 207(f).
`(C) INTERGOVERNMENTAL PERSONNEL ACT- The Director may accept as personnel for
the BARDA, employees under subchapter VI of chapter 33 of subpart B of part III
of title 5, United States Code.
`(D) OTHER SERVICES- The Director may accept voluntary and uncompensated
services.
`(c) National Biodefense Advisory Board-
`(1) IN GENERAL-
`(A) PURPOSE- The National Biodefense Advisory Board shall provide expert advice
and guidance to the Secretary on the threats, challenges, and opportunities
presented by advances in biological and life sciences and the threat from
natural infectious diseases and chemical, biological, radiological, and nuclear
threats.
`(B) MEMBERSHIP- There is established the National Biodefense Advisory Board
(hereinafter in this section referred to as the `Board') to be composed of 23
members who represent the Nation's preeminent scientific, public health, and
medical experts on the subject of biological, chemical, nuclear, and
radiological threats, whether naturally occurring, accidental, or deliberate, as
follows:
`(i) EX OFFICIO- The following members shall serve on the Board ex officio:
`(I) The Assistant to the President for Homeland Security and Counterterrorism.
`(II) The Director of the Office of Science and Technology Policy.
`(III) The Assistant Secretary for Public Health Emergency Preparedness.
`(IV) The Director of the National Institutes of Health.
`(V) The Director of the Centers for Disease Control and Prevention.
`(VI) The Commissioner of Food and Drugs.
`(VII) The Director of BARDA.
`(VIII) The Assistant Secretary of Defense for Health Affairs.
`(IX) The Assistant Secretary of Homeland Security for Science and Technology.
`(X) The Secretary of Agriculture (or a designee).
`(ii) APPOINTED MEMBERS- The following individuals, as appointed by the
Secretary:
`(I) Four representatives of the pharmaceutical and biotechnology industries.
`(II) Four representatives of academia.
`(III) Five other members as determined appropriate by the Secretary.
`(C) TERM OF APPOINTMENT- A member of the Board described in subparagraph (B)(ii)
shall serve for a term of 3 years, except that the Secretary may adjust the
terms of the initial Board appointees in order to provide for a staggered term
of appointment for all members.
`(D) CONSECUTIVE APPOINTMENTS; MAXIMUM TERMS- A member may be appointed to serve
not more than 3 terms on the Board and may serve not more than 2 consecutive
terms.
`(2) DUTIES- The Board shall--
`(A) advise the Secretary on major biodefense initiatives and review ongoing and
proposed biodefense programs, which may include potential activities of the
BARDA; and
`(B) in consultation with the Director of BARDA, and in coordination with the
Director of National Institute of Allergy and Infectious Diseases, provide to
the Secretary, recommendations and findings for an expanded, intensified, and
coordinated biodefense research program encompassing the programs of the BARDA
and other Federal agencies and related programs of the other research
institutes.
`(3) MEETINGS- The Board shall meet at the call of the Secretary, but in no case
less than twice annually to provide to the Secretary updated assessments,
findings, and recommendations of the current trends, challenges, and
opportunities posed in biotechnology and genetic engineering.
`(4) VACANCIES- Any vacancy in the Board shall not affect its powers, but shall
be filled in the same manner as the original appointment.
`(5) CHAIRPERSON- The Secretary shall appoint a chairperson from among the
members of the Board.
`(6) POWERS-
`(A) HEARINGS- The Board may hold such hearings, sit and act at such times and
places, take such testimony, and receive such evidence as the Board considers
advisable to carry out this subsection.
`(B) POSTAL SERVICES- The Board may use the United States mails in the same
manner and under the same conditions as other departments and agencies of the
Federal Government.
`(7) PERSONNEL-
`(A) OFFICERS OF THE FEDERAL GOVERNMENT- A member of the Board that is an
employee of the Federal Government may not receive additional pay, allowances,
or benefits by reason of the member's service on the Board.
`(B) OTHER MEMBERS- A member of the Board that is not an employee of the Federal
Government shall be compensated at a rate equivalent to the daily equivalent of
the annual rate of basic pay prescribed for level IV of the Executive Schedule
under section 5315 of title 5, United States Code, for each day (including
travel time) during which the member is engaged in the actual performance of
duties as a member of the Board.
`(C) TRAVEL EXPENSES- Each member of the Board shall receive travel expenses,
including per diem in lieu of subsistence, in accordance with applicable
provisions under subchapter I of chapter 57 of title 5, United States Code.
`(D) DETAIL OF GOVERNMENT EMPLOYEES- Any Federal Government employee may be
detailed to the Board without reimbursement, and such detail shall be without
interruption or loss of civil service status or privilege.
`(d) FUND-
`(1) ESTABLISHMENT- There is established the Biodefense Medical Countermeasure
Development Fund, which shall be administered by the Director of the BARDA.
`(2) FUNDS-
`(A) FIRST FISCAL YEAR- Of the amounts appropriated to carry out the Project
BioShield Act of 2004 (Public Law 108-276) and not obligated, $1,000,000,000
shall be available to the Fund to carry out this section for fiscal year 2006.
--------------------------------------------------------------------------------
S.1873
Biodefense and Pandemic Vaccine and Drug Development Act of 2005 (Reported in
Senate)
--------------------------------------------------------------------------------
Beginning
October 17, 2005
[Strike out all after the enacting clause and insert the part printed in italic]
[Struck out->] SECTION 1. SHORT TITLE. [<-Struck out]
[Struck out->] SEC. 2. TABLE OF CONTENTS. [<-Struck out]
[Struck out->] SEC. 3. BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AGENCY.
[<-Struck out]
[Struck out->] `SEC. 319L. BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AGENCY.
[<-Struck out]
[Struck out->] SEC. 4. CLARIFICATION OF COUNTERMEASURES COVERED BY PROJECT
BIOSHIELD. [<-Struck out]
[Struck out->] SEC. 5. ORPHAN DRUG MARKET EXCLUSIVITY FOR COUNTERMEASURE
PRODUCTS. [<-Struck out]
[Struck out->] `SEC. 505C. ORPHAN DRUG MARKET EXCLUSIVITY FOR COUNTERMEASURE
PRODUCTS. [<-Struck out]
[Struck out->] SEC. 6. LIABILITY PROTECTIONS FOR PANDEMICS, EPIDEMICS, AND
COUNTERMEASURES. [<-Struck out]
[Struck out->] SEC. 7. COMPENSATION. [<-Struck out]
[Struck out->] `PART D--OTHER COMPENSATION PROGRAMS [<-Struck out]
[Struck out->] `SEC. 271. COVERED COUNTERMEASURES PROGRAM. [<-Struck out]
[Struck out->] SEC. 9. TECHNICAL ASSISTANCE. [<-Struck out]
[Struck out->] `SEC. 565. TECHNICAL ASSISTANCE. [<-Struck out]
[Struck out->] SEC. 10. ANIMAL MODELS FOR CERTAIN DISEASES. [<-Struck out]
[Struck out->] `SEC. 409J. ANIMAL MODELS FOR CERTAIN DISEASES. [<-Struck out]
[Struck out->] SEC. 11. ANIMAL MODEL/RESEARCH TOOL SCIENTIFIC ADVISORY
COMMITTEE. [<-Struck out]
[Struck out->] `SEC. 566. ANIMAL MODEL/RESEARCH TOOL SCIENTIFIC ADVISORY
COMMITTEE. [<-Struck out]
[Struck out->] SEC. 12. COLLABORATION AND COORDINATION. [<-Struck out]
[Struck out->] SEC. 13. PROCUREMENT. [<-Struck out]
[Struck out->] SEC. 14. NATIONAL PATHOLOGY CENTER. [<-Struck out]
[Struck out->] `Subpart 7--National Pathology Center [<-Struck out]
[Struck out->] `SEC. 485A. ESTABLISHMENT OF NATIONAL PATHOLOGY CENTER. [<-Struck
out]
[Struck out->] `SEC. 485B. PURPOSES AND FUNCTIONS OF THE CENTER. [<-Struck out]
[Struck out->] `SEC. 485C. BOARD OF REGENTS. [<-Struck out]
[Struck out->] `SEC. 485D. GIFTS TO THE CENTER. [<-Struck out]
[Struck out->] `SEC. 485E. CENTER FACILITIES. [<-Struck out]
SECTION 1. SHORT TITLE.
SEC. 2. TABLE OF CONTENTS.
SEC. 3. BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AGENCY.
`SEC. 319L. BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AGENCY.
SEC. 4. CLARIFICATION OF COUNTERMEASURES COVERED BY PROJECT BIOSHIELD.
SEC. 5. ORPHAN DRUG MARKET EXCLUSIVITY FOR COUNTERMEASURE PRODUCTS.
`SEC. 505C. ORPHAN DRUG MARKET EXCLUSIVITY FOR COUNTERMEASURE PRODUCTS.
SEC. 6. LIABILITY PROTECTIONS FOR PANDEMICS, EPIDEMICS, AND COUNTERMEASURES.
`SEC. 319F-3. LIABILITY PROTECTIONS FOR PANDEMIC AND EPIDEMIC PRODUCTS AND
SECURITY COUNTERMEASURES.
SEC. 7. COMPENSATION.
`PART D--OTHER COMPENSATION PROGRAMS
`SEC. 271. COVERED COUNTERMEASURES PROGRAM.
SEC. 9. TECHNICAL ASSISTANCE.
`SEC. 565. TECHNICAL ASSISTANCE.
SEC. 10. ANIMAL MODELS FOR CERTAIN DISEASES.
`SEC. 409J. ANIMAL MODELS FOR CERTAIN DISEASES.
SEC. 11. ANIMAL MODEL/RESEARCH TOOL SCIENTIFIC ADVISORY COMMITTEE.
`SEC. 566. ANIMAL MODEL/RESEARCH TOOL SCIENTIFIC ADVISORY COMMITTEE.
SEC. 12. COLLABORATION AND COORDINATION.
SEC. 13. PROCUREMENT.
SEC. 14. NATIONAL PATHOLOGY CENTER.
`Subpart 7--National Pathology Center
`SEC. 485A. ESTABLISHMENT OF NATIONAL PATHOLOGY CENTER.
`SEC. 485B. PURPOSES AND FUNCTIONS OF THE CENTER.
`SEC. 485C. BOARD OF REGENTS.
`SEC. 485D. GIFTS TO THE CENTER.
`SEC. 485E. CENTER FACILITIES.
SEC. 15. RULE OF CONSTRUCTION.
October 24, 2005
---------------------------------------------------------------
http://thomas.loc.gov/cgi-bin/query/D?r109:1:./temp/~r109RHmfcu::
REPORTS OF COMMITTEES -- (Senate - October 24, 2005)
[Page: S11768] GPO's PDF
--- The following reports of committees were submitted:
By Mr. INHOFE, from the Committee on Environment and Public Works, with an
amendment in the nature of a substitute:
S . 1409. A bill to amend the Safe Drinking Water Act Amendments of 1996 to
modify the grant program to improve sanitation in rural and Native villages in
the State of Alaska (Rept. No. 109-159).
By Mr. ENZI, from the Committee on Health, Education, Labor, and Pensions, with
an amendment in the nature of a substitute:
S . 1873 . A bill to prepare and strengthen the biodefenses of the United States
against deliberate, accidental, and natural outbreaks of illness, and for other
purposes.
------------------------------------------------------------------------------
http://thomas.loc.gov/cgi-bin/query/D?r109:2:./temp/~r109RHmfcu::
INTRODUCTION OF BILLS AND JOINT RESOLUTIONS -- (Senate - October 17, 2005)
[Page: S11421] GPO's PDF
--- The following bills and joint resolutions were introduced, read the first
and second times by unanimous consent, and referred as indicated:
By Mr. INHOFE (for himself, Mr. JEFFORDS, and Mr. CHAFEE):
S . 1869. A bill to reauthorize the Coastal Barrier Resources Act, and for other
purposes; to the Committee on Environment and Public Works.
By Mrs. FEINSTEIN:
S . 1870. A bill to clarify the authorities for the use of certain National Park
Service properties within Golden Gate National Recreation Area and San Francisco
Maritime National Historical Park, and for other purposes; to the Committee on
Energy and Natural Resources.
By Ms. COLLINS:
S . 1871. An original bill to repeal the increased micropurchase threshold; from
the Committee on Homeland Security and Governmental Affairs; placed on the
calendar.
[Page: S11422] GPO's PDF By Ms. LANDRIEU (for herself and Mr. VITTER):
S . 1872. A bill to permit the cancellation of certain loans under the Robert T.
Stafford Disaster Relief and Emergency Assistance Act; to the Committee on
Homeland Security and Governmental Affairs.
By Mr. BURR (for himself, Mr. ENZI, Mr. GREGG, Mr. FRIST, and Mr. ALEXANDER):
S . 1873 . A bill to prepare and strengthen the biodefenses of the United
States against deliberate, accidental, and natural outbreaks of illness, and for
other purposes; to the Committee on Health, Education, Labor, and Pensions.
By Mrs. FEINSTEIN:
S . 1874. A bill to amend title 28, United States Code, to clarify jurisdiction
of Federal Courts over a tort action brought by an alien, and for other
purposes; to the Committee on the Judiciary.
By Mr. BINGAMAN:
S . 1875. A bill to provide financial aid to local law enforcement officials
along the Nation's borders, and for other purposes; to the Committee on the
Judiciary.
By Mr. AKAKA:
S . 1876. A bill to provide that attorneys employed by the Department of Justice
shall be eligible for compensatory time off for travel under section 5550b of
title 5, United States Code; to the Committee on Homeland Security and
Governmental Affairs.
By Mr. BAUCUS:
S . 1877. A bill to prohibit the closure or relocation of certain county offices
of the Farm Service Agency; to the Committee on Agriculture, Nutrition, and
Forestry.
By Mr. AKAKA:
S . 1878. A bill to prohibit predatory payday loans, and for other purposes; to
the Committee on Banking, Housing, and Urban Affairs.
By Mr. AKAKA:
S . 1879. A bill to amend title 11, United States Code, to limit claims in
bankruptcy by certain unsecured creditors; to the Committee on the Judiciary.
By Mr. KENNEDY (for himself, Mr. DODD, Mr. HARKIN, Ms. MIKULSKI, Mr. BINGAMAN,
Mrs. CLINTON, Mr. SCHUMER, and Mr. OBAMA):
S . 1880. A bill to amend the Public Health Service Act to enhance biodefense
and pandemic preparedness activities, and for other purposes; to the Committee
on Health, Education, Labor, and Pensions.
----------------------------------------------------------------------